Quick Answer
SINOVAC BIOTECH LTD reported Cash and Equivalents of $1.27 billion for fiscal year 2023.
SINOVAC BIOTECH LTD Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $1.27B | -70.3% |
| 2022 | $4.28B | -63.1% |
| 2021 | $11.61B | +1015.2% |
| 2020 | $1.04B | +581.7% |
| 2019 | $152.72M | -3.4% |
| 2018 | $158.17M | +38.2% |
| 2017 | $114.42M | +83.3% |
| 2016 | $62.43M | -2.2% |
| 2015 | $63.83M | -28.9% |
| 2014 | $89.79M | -15.7% |
| 2013 | $106.52M | +16.8% |
| 2012 | $91.22M | -12.5% |
| 2011 | $104.29M | +2.7% |
| 2010 | $101.58M | +35.5% |
| 2009 | $74.95M | +127.9% |
| 2008 | $32.89M | — |
- SINOVAC BIOTECH LTD showed a decrease of -70.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2023 period, SINOVAC BIOTECH LTD’s cash and equivalents has grown by 3761.3% (from $32.89 million to $1.27 billion).
- The most recent figure is from SINOVAC BIOTECH LTD’s fiscal year 2023 report (Form 20-F), filed with the SEC on April 29, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: